HY-P0070_thymus peptide C_MCE
Data Sheet
BIOLOGICAL ACTIVITY:
Thymus Peptide C is extracted from the thymus glands of young calves, is a hormonal drug and may show synergism with certain pituitary hormones, somatotropin hormone, and estrogens.
Thymus Peptide C antagonizes the adrenocortical hormones' effect on the lymphatic system. Thymus Peptide C works as a substitute for the physiological functions of the thymus. With T–cell deficiency, Thymus Peptide C recruits immature system cells in the bone marrow and stimulates their maturation to the fully active T–cell phase in the lymphatic system. Thymus Peptide C increases granulopoiesis and erythropoiesis by acting on the bone marrow. The preparation can be used for all diseases with primary and secondary immune system disturbances involving T–cells which are thymus dependent and for a wide range of symptoms such as chronic viral, bacterial and fungal infections; allergic and auto–immune reactions; and certain lymphoproliferative syndromes.
Product Name:thymus peptide C Cat. No.:HY-P0070CAS No.:
316791-23-8Molecular Formula:CH 3Molecular Weight:15.03Target:Others Pathway:Others Solubility:
10 mM in H 2
O
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@https://www.360docs.net/doc/ef5612512.html,
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Certificate of Analysis
PHYSICAL AND CHEMICAL PROPERTIES
Molecular Formula:CH 3Molecular Weight:15.03Storage:
Powder -20°C 3 years 4°C 2 years In solvent
-80°C 6 months -20°C
1 month
Chemical Structure:
ANALYTICAL DATA
Appearance:Colorless to light yellow (Liquid)Purity:>98.0%
Conclusion:
The product has been tested and complies with the given specifications.
Product Name:thymus peptide C Cat. No.:HY-P0070CAS No.:316791-23-8Batch No.:19139
Chemical Name:
Thymus Peptide C (9CI)
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@https://www.360docs.net/doc/ef5612512.html,
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Safety Data Sheet Revision Date:Sep.-15-2017
Print Date:Sep.-15-2017
1. PRODUCT AND COMPANY IDENTIFICATION
1.1 Product identifier
Product name :thymus peptide C
Catalog No. :HY-P0070
CAS No. :316791-23-8
1.2 Relevant identified uses of the substance or mixture and uses advised against
Identified uses :Laboratory chemicals, manufacture of substances.
1.3 Details of the supplier of the safety data sheet
Company:MedChemExpress USA
Tel:609-228-6898
Fax:609-228-5909
E-mail:sales@https://www.360docs.net/doc/ef5612512.html,
1.4 Emergency telephone number
Emergency Phone #:609-228-6898
2. HAZARDS IDENTIFICATION
2.1 Classification of the substance or mixture
Not a hazardous substance or mixture.
2.2 GHS Label elements, including precautionary statements
Not a hazardous substance or mixture.
2.3 Other hazards
None.
3. COMPOSITION/INFORMATION ON INGREDIENTS
3.1 Substances
Synonyms:None
Formula:CH3
Molecular Weight:15.03
CAS No. :316791-23-8
4. FIRST AID MEASURES
4.1 Description of first aid measures
Eye contact
Remove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.
Skin contact
Rinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.
Inhalation
Immediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.
Ingestion
Wash out mouth with water; Do NOT induce vomiting; call a physician.
4.2 Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2).
4.3 Indication of any immediate medical attention and special treatment needed
Treat symptomatically.
5. FIRE FIGHTING MEASURES
5.1 Extinguishing media
Suitable extinguishing media
Use water spray, dry chemical, foam, and carbon dioxide fire extinguisher.
5.2 Special hazards arising from the substance or mixture
During combustion, may emit irritant fumes.
5.3 Advice for firefighters
Wear self-contained breathing apparatus and protective clothing.
6. ACCIDENTAL RELEASE MEASURES
6.1 Personal precautions, protective equipment and emergency procedures
Use full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.
Refer to protective measures listed in sections 8.
6.2 Environmental precautions
Try to prevent further leakage or spillage. Keep the product away from drains or water courses.
6.3 Methods and materials for containment and cleaning up
Absorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.
7. HANDLING AND STORAGE
7.1 Precautions for safe handling
Avoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.
7.2 Conditions for safe storage, including any incompatibilities
Keep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.
Recommended storage temperature:Powder-20°C 3 years
4°C 2 years
In solvent-80°C 6 months
-20°C 1 month
Shipping at room temperature if less than 2 weeks.
7.3 Specific end use(s)
No data available.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
8.1 Control parameters
Components with workplace control parameters
This product contains no substances with occupational exposure limit values.
8.2 Exposure controls
Engineering controls
Ensure adequate ventilation. Provide accessible safety shower and eye wash station.
Personal protective equipment
Eye protection Safety goggles with side-shields.
Hand protection Protective gloves.
Skin and body protection Impervious clothing.
Respiratory protection Suitable respirator.
Environmental exposure controls Keep the product away from drains, water courses or the soil. Clean
spillages in a safe way as soon as possible.
9. PHYSICAL AND CHEMICAL PROPERTIES
9.1 Information on basic physical and chemical properties
Appearance Colorless to light yellow (Liquid)
Odor No data available
Odor threshold No data available
pH No data available
Melting/freezing point No data available
Boiling point/range No data available
Flash point No data available
Evaporation rate No data available
Flammability (solid, gas)No data available
Upper/lower flammability or explosive limits No data available
Vapor pressure No data available
Vapor density No data available
Relative density No data available
Water Solubility No data available
Partition coefficient No data available
Auto-ignition temperature No data available
Decomposition temperature No data available
Viscosity No data available
Explosive properties No data available
Oxidizing properties No data available
9.2 Other safety information
No data available.
10. STABILITY AND REACTIVITY
10.1 Reactivity
No data available.
10.2 Chemical stability
Stable under recommended storage conditions.
10.3 Possibility of hazardous reactions
No data available.
10.4 Conditions to avoid
No data available.
10.5 Incompatible materials
Strong acids/alkalis, strong oxidising/reducing agents.
10.6 Hazardous decomposition products
Under fire conditions, may decompose and emit toxic fumes.
Other decomposition products - no data available.
11.TOXICOLOGICAL INFORMATION
11.1 Information on toxicological effects
Acute toxicity
Classified based on available data. For more details, see section 2
Skin corrosion/irritation
Classified based on available data. For more details, see section 2
Serious eye damage/irritation
Classified based on available data. For more details, see section 2
Respiratory or skin sensitization
Classified based on available data. For more details, see section 2
Germ cell mutagenicity
Classified based on available data. For more details, see section 2
Carcinogenicity
IARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.
ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.
NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.
OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.
Reproductive toxicity
Classified based on available data. For more details, see section 2
Specific target organ toxicity - single exposure
Classified based on available data. For more details, see section 2
Specific target organ toxicity - repeated exposure
Classified based on available data. For more details, see section 2
Aspiration hazard
Classified based on available data. For more details, see section 2
12. ECOLOGICAL INFORMATION
12.1 Toxicity
No data available.
12.2 Persistence and degradability
No data available.
12.3 Bioaccumlative potential
No data available.
12.4 Mobility in soil
No data available.
12.5 Results of PBT and vPvB assessment
PBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.
12.6 Other adverse effects
No data available.
13. DISPOSAL CONSIDERATIONS
13.1 Waste treatment methods
Product
Dispose substance in accordance with prevailing country, federal, state and local regulations.
Contaminated packaging
Conduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.
14. TRANSPORT INFORMATION
DOT (US)
This substance is considered to be non-hazardous for transport.
IMDG
This substance is considered to be non-hazardous for transport.
IATA
This substance is considered to be non-hazardous for transport.
15. REGULATORY INFORMATION
SARA 302 Components:
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components:
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards:
No SARA Hazards.
Massachusetts Right To Know Components:
No components are subject to the Massachusetts Right to Know Act.
Pennsylvania Right To Know Components:
No components are subject to the Pennsylvania Right to Know Act.
New Jersey Right To Know Components:
No components are subject to the New Jersey Right to Know Act.
California Prop. 65 Components:
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.
16. OTHER INFORMATION
Copyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@https://www.360docs.net/doc/ef5612512.html,
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
各种胜肽的作用
胜肽就是peptide也就是小分子蛋白质，在美国等国家的护肤品中已经很流行，因为它成分先进，效果显著，被很多药妆品牌使用。但是胜肽的价格很贵，所以添加了胜肽的产品也卖的比较贵。 简单化，胜肽就是氨基酸（蛋白质的最小单位）数目在2-10之间的蛋白质。这些胜肽按照含有氨基酸的数目不同可以分为二胜肽（含两个氨基酸），三胜肽（含三个氨基酸），四胜肽……等等.而由于含有的氨基酸的品种不同，二胜肽也有不同的品种，三胜肽也是这样，所以就出现了现下各种作用，各种名字的胜肽。但总结一下， 主要有以下5种︰那几种胜肽，对其皮肤的作用。 1. 抑制SNARE接受体的合成，抑制肌肤的儿茶酚胺 (catecholamine)和乙酰胆碱(acetylcholine)过度释放，局部阻断神经传递肌肉收缩信息，影响皮壤神经传导，使脸部肌肉放松，达到平抚动态纹、静态纹及细纹的。这类胜肽有︰ 六胜肽 (Acetyl hexapeptide-3 = Ac-EEMQRR-NH2, 又称Argireline ) 五胜肽 (Pentapeptide-3, 又称Leuphasyl) 七胜肽 (Heptapeptide, 又称snap 7) 八胜肽 (Acetyl Octapeptide-3, 又称snap 8) 二胜肽 (Dipeptide diaminobutyroyl benzylamide, 又称Syn Ake) 五胜肽 (Pentapeptide-3,俗称vialox) 2. 促进胶原蛋白，弹力纤维和透明质酸增生，提升肌肤的含水量，增加皮肤浓度以及减少细纹。这类胜肽有︰ 五胜肽 (Palmitoyl Pentapeptide-3 =Palmitoyl-KTTKS, 又称Matrixyl) 六胜肽 (Hexapeptide-10,俗称Serilesine) 寡胜肽 (Palmitoyl Oligopeptide) 3. 抗羰化，保护胶原不会被活性碳基团损伤，促进III型胶原的生长;抗氧化；抗醣化。这类胜肽有︰ 二胜肽 (俗称carnosine) 三胜肽 (俗称Aldeline) 三胜肽 (铜胜肽 =copper peptide= GHK-Cu)
大豆小分子肽详细介绍
大豆多肽 大豆多肽(soy peptide) ,即肽基大豆蛋白水解产物( peptide - based soy protein hydroly-sate)的简称。它来源于大豆蛋白质的酶解产物，是大豆蛋白质经蛋白酶作用后，再经特殊处理而得到的蛋白质水解产物。大豆中的蛋白质含量高，质量好，营养价值很高，与牛肉的营养价值大致相当。大豆蛋白质所含必需氨基酸种类全面，数量丰富,必需氨基酸模式(氨基酸比值)与人体需求较接近,消化率也较高。大豆多肽通常是由3~6个氨基酸组成的低肽混合物,相对分子质量分布以低于1000D的为主，主要出峰位置在相对分子量300 -700D范围内。其氨基酸的组成与大豆球蛋白十分相似，必需氨基酸的平衡良好,含量也很丰富,因此营养价值很高。 大豆多肽的特点 (一)黏度较低，溶解度较高 大豆蛋白的黏度随浓度的增加而显著增加。因此，大豆蛋白的浓度不能提得太高,超过13%就会形成凝胶状。若加工成酸性蛋白饮料时，pH值接近4.5左右(大豆蛋白的等电点)时就会产生沉淀。而大豆多肽则没有上述缺点。它的黏度较低而溶解度较高，这是因为水解物的分子量减小了；水解后产生了一些可离解的氨基和羧基基团,增加了水解物的亲水性。与大豆蛋白质相比，大豆多肽具有以下特点:①即使在高浓度时,其黏度较低:②在较宽的pH值范围内仍能保持溶解状态;③吸湿性与保湿性好。大豆多肽的这些性质有利于开发新产品。 (二)渗透压不高 大豆多肽溶液的渗透压的大小处于大豆蛋白与同一组成氨基酸混合物之间。当一种溶液的渗透压比体液高时,易使人体消化道周围组织细胞中的水分向胃肠腔内移动而出现腹泻。氨基酸类食品口服易发生这类问题。大豆多肽的渗透压比氨基酸的低得多。因此，大豆多肽可作为口服营养液使用。 (三)吸湿性，保湿性强 大豆多肽的吸湿性和保湿性比胶原蛋白多肽和丝蛋白多肽更强,这一特性非常适合于日 用化学工业用来配制护发膏及护发霜。 (四)能调节产品质构 大豆多肽具有抑制蛋白质形成凝胶的特性,可用来调整食品的硬度与质构。例如，水产品肉禽蛋白质及大豆蛋白质在加热时会形成凝胶，或面粉在形成面团时都会使质构变硬，如果添加一定量的大豆多肽,就会起到软化凝胶的作用。这一特性，可应用于火腿、香肠、鱼糕等高蛋白食品的软化。 大豆多肽的功能特性 大豆多肽即“多肽基大豆蛋白水解物"的简称,是大豆蛋白质经蛋白酶作用或微生物技术
tutor speptide例子的翻译
Gromacs online 教程上面的一个关于speptide的模拟的教程： 模拟的对象是一种由胰脏分泌的消化酶Ribonuclease A被subtilisin（枯草杆菌蛋白酶）切割后产生的S多肽复合物，叫Ribonuclease S-peptide，具有催化活性。由于Ribonuclease S-peptide这种小的肽链在水溶液中含有大量的alpha螺旋结构，所以针对这种小肽链人们展开了很多实验和理论方面的研究。 关于s－peptide的所有文件都在目录tutor/speptide之中。我们可以从蛋白数据文库当中获得所需的关于s-peptide的初始结构的文件。事实上，Ribonuclease S有很多的结构，我们只从中挑选了一个结构，取其头20个残基作为切割后的s－peptide的结构存入184speptide.pdb文件中。可以用命令 more speptide.pdb 来浏览pdb文件的内容。 如果有像rasmol这样的分子作图程序，还可以将分子在屏幕上显示出来： rasmol speptide.pdb 用Gromacs进行分子动力学模拟的七个必要步骤： 1.将pdb文件转换成一个Gromacs结构文件（.gro）和一个Gromacs拓扑文件（.top）； 2.将蛋白（多肽）溶解(in water)； 3.能量最小化； 4.加上必须的离子（对于speptide而言这步可以省略。）； 5.Short MD run，目的是为了进行一次位置受限的MD； 6.Full MD；
7.数据分析。 8.em, pr, md每一模拟都要收敛！逐步模拟方法使模拟过程平稳不易崩溃！ 以下详细描述如何在speptide的模拟中完成这些步骤。 如何由pdb文件产生gro和top文件？ 可以由pdb2gmx程序产生gro和top文件，命令如下： pdb2gmx -f speptide.pdb -p speptide.top -o speptide.gro 注意命令行参数中，输出文件的扩展名必须正确。这样，在程序运行中就只需要选择力场便可以了，选择0。其实还可以在pdb2gmx程序中选择粒子注入，在多肽的N端或者是C端加上一些残基。可以使用命令 pdb2gmx -h 来查看关于pdb2gmx命令的参数的详细描述。 pdb2gmx程序产生了一个分子拓扑文件speptide.pdb和一个gromacs结构文件speptide.gro，gro文件包括氢原子的位点。Pdb2gmx的-p参数和-o参数是可选的，如果我们没有输入这两个参数，将默认产生topol.top和conf.gro文件。现在可以来看看pdb2gmx文件的输出文件speptide.gro和speptide.top more speptide.gro more speptide.top 可以看出，gro文件和pdb文件非常类似，只是文件版面稍有不同，而top文件中则包含了像原子类型，原子之间的键，以及其他一些附加信息。 将多肽溶解于一个充满水的周期盒子中
3X FLAG Peptide_合成的标签肽_Apexbio
3X FLAG Peptide sales@https://www.360docs.net/doc/ef5612512.html, 引用文章 1.Carpenter, Brandon S., et al. "The heterotrimeric kinesin-2 complex interacts with and regulates GLI protein function." Journal of cell science 128.5 (2015): 1034- 1050.PMID:25588831 质量控制 质量控制和MSDS View current batch:2 Purity = 98.77% COA (Certificate Of Analysis) HPLC MS (Mass Spectrometry) MSDS (Material Safety Data Sheet) 0.25mg/ml 3*flag peptide was used to elute flag-resin immunoprecipitated proteins expressed by 293T cells. Purified protein band was indicated by arrow.150ug/ml 3XFLAG peptide was used to elute FLAG tagged HSP90 protein. Elution was performed at 4 degrees and 2
化学性质 CAS号SDF Download SDF 别名H-Met-Asp-Tyr-Lys-Asp-His-Asp-Gly-Asp-Tyr-Lys-Asp-His-Asp-Ile-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-OH 化学名3X FLAG Peptide SMILES CCC(C)C(C(=O)NC(CC(=O)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CCCCN)C(=O)NC(CC(=O)O)C(=O)NC(CC(=O)O)C(=O)NC(CC(=O)O)C(=O )NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)O)NC(=O)C(CC(=O)O)NC(=O)C(CC2=CNC=N2)NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(CC3=CC =C(C=C3)O)NC(=O)C(CC(=O)O)NC( 分子式C120H169N31O49S分子量2861.87 溶解性Soluble in water or 1% acetic acid储存条件Desiccate at -20°C 一般建议为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。储液可以在零下20℃中保存数月。 运输条件试用装：蓝冰运输。 其他可选规格：常温运输或根据您的要求用蓝冰运输。 生物活性 描述3X FLAG Peptide是一个合成的含有三个重复DYKXXD氨基酸序列的多肽。 靶点anti-flag M2 antibody IC50 实验报告 ELISA实验[1]： 溶解方法该多肽在无菌水中的溶解度>10 mM，原液应分装并储存在-80℃，可储存几个月。 应用3-Flag peptide被广泛用作一种温和的纯化试剂，用于Flag表位标记重组蛋白的纯化。尽管在缺乏钙离子时，其亲和柱会释放单价标记蛋白，但是抗体仍保留对Flag序列的亲和性，即使在无金属存在的条件下，因此不能用来进行金属敏感的ELISA实验。当Flag标记蛋白结合在ELISA板或印迹过滤器上时，抗体仍然与多价表面包被抗原结合。抗原多价性提高了Flag抗体的亲和性，使得ELISA反应不依赖于钙离子。然而，当抗体本身是单价的，即通过蛋白水解变成Fab，ELISA反应即变为钙依赖的。这种金属依赖的ELISA实验被用于研究抗体对金属的需求。在二价金属中，比钙半径大或比钙半径小的金属其结合均逐渐减少。几种更小的金属，比如镍，充当结合反应的抑制剂。重金属如镉、镧和钐可以与抗体结合。由于对该抗体与重组Flag融合蛋白共结晶的兴趣，其与重金属结合的能力就变得非常有意义。 References: 1. Hopp TP1, Gallis B, Prickett KS. Metal-binding properties of a calcium-dependent monoclonal antibody. Mol Immunol. 1996 May-Jun;33(7-8):601-8. Background FLAG标签是将亲水性的8个氨基酸与目的蛋白进行融合。FLAG标签可以与抗体M1结合。3× FLAG标签系统大幅度提高了FLAG标签的检测能力。三串联的FLAG表位是亲水性的，22个氨基酸的长链，它最多可以检测10 fmol的融合蛋白。FLAG标记的Pyrococcus furiosus的麦芽糊精结合蛋白已经获得了晶体，晶体结果显示FLAG标签对蛋白晶体质量没有多大影响。 FLAG标签可以用肠激酶法处理去除，肠激酶能够特异性的作用于C端的5个氨基酸多肽序列。 参考文献： 1. Hopp TP, Prickett KS, Price VL, Libby RT, March CJ, Ceretti DP, Urdal DL, Conlon PJ (1988) A short polypeptide marker sequence useful for recombinant protein identification and purification. Bio/Technology 6:1204–1210. 2. Hopp TP, Gallis B, Prikett KS (1996) Metal-binding properties of a calcium dependent monoclonal antibody. Mol Immunol 33:601–608. 3. Einhauer A, Jungbauer A (2000) Kinetics and thermodynamical properties of the monoclonal antibody M1 directed against the FLAG peptide. 20th International symposium on the separation of proteins, peptides, and polynucleotides (ISPPP). Lublijana, Slovenia, November 5–8, 2000. 4. Bucher MH, Evdokimov AG, Waugh DS (2002) Differential effects of short affinity tags on the crystallization of Pyrococcus furiosus maltodextrin-binding protein. Biol Cryst 58:392–397. 5. Maroux S, Baratti J, Desnuelle P (1971) Purification and specificity of procine enterokinase. J Biol Chem 246:5031–5039.
Protein and Peptide Letters 投稿须知
在线提交稿件：在这个网址注册并提交 稿件应由作者本人(作者之一)提交，其他人代表提交无效。有多位作者时，主要作者/相关作者应提交一份附信，以代表其他合著者。 拒绝一稿多投，有曾发表过的图片、表格，应该声明，并获得相关版权。 需要一并提交的还包括：所有材料（主要的MS word或T eX/LaT e文本），图表/插画要求用TIFF，PDF或JPEG格式，化学结构式用ChemDraw/ISISDraw （TGF）制作，同时附带包含上述所有材料的PDF版本稿件。 文件的命名要求有相关作者的名字，例如“Cilli MS text.doc”，“Cilli MS Figure 1”。 提交前，谨慎审查稿件中的特殊字符、数学符号、希腊字母、等式、表格、参考文献和图片，保证它们的格式正确。 参考文献、图表、化学结构式等第一次出现时，应该在适当的位置标注援引。图表还应具有标题或说明。 在线提交稿件成功后，作者会收到系统自动生成的通知。 稿件出版：本杂志发表用英文撰写的文章，包括同行审阅的短篇综述，通讯，研究论文和结晶报告等。 稿件长度： 短篇综述：不超过9页，每页平均900个字。 通讯文章：字数介于3000-6000。 研究文章：字数介于4000-8000. 结晶报告：不超过4页，每页平均900个字。 对于图片、表格或者附件（视频短片、动画、数据）的数量，不设上限，可以随文章同时线上提交。作者提交的每篇文章都应包含支持性的数据（具体要求参考补充材料部分）。 稿件准备： 所投稿件应使用英文书写，并且形式清晰、直接、兼具灵活。稿件的所有页码都应按顺序标明页码，便于后续的审稿和编辑。 为了进一步方便投稿人做好稿件的准备工作，可以通过访问
小鼠C肽 (C-Peptide)-ELISA试剂盒说明书
小鼠C肽 (C-Peptide)酶联免疫吸附测定试剂盒 使用说明书 产品编号：E-EL-M0354 （本试剂盒仅供体外研究使用、不用于临床诊断!） 声明：尊敬的客户，感谢您选用本公司的产品。本产品选用世界著名生产厂家的原料，采用专业ELISA kit生产技术制造。适用于体外定量检测小鼠血清、血浆、组织匀浆或细胞培养上清液中天然和重组C-Peptide浓度。使用前请仔细阅读说明书并检查试剂组分！如有疑问，请及时联系伊莱瑞特生物科技有限公司。 *: [96T/48T]（打开包装后请及时检查所有物品是否齐全完整）
检测原理: 本试剂盒采用双抗体夹心ELISA法。用抗小鼠C-Peptide抗体包被于酶标板上，实验时标本或标准品中的C-Peptide会与包被抗体结合，游离的成分被洗去。依次加入生物素化的抗小鼠C-Peptide 抗体和辣根过氧化物酶标记的亲和素。抗小鼠C-Peptide抗体与结合在包被抗体上的小鼠C-Peptide 结合、生物素与亲和素特异性结合而形成免疫复合物，游离的成分被洗去。加入显色底物(TMB)，TMB在辣根过氧化物酶的催化下现蓝色，加终止液后变黄。用酶标仪在450nm波长处测OD值，C-Peptide浓度与OD450值之间呈正比，通过绘制标准曲线求出标本中C-Peptide的浓度。 标本收集: 1.血清：全血标本于室温放置2小时或4℃过夜后于1000×g离心20分钟，取上清即可检测，收集 血液的试管应为一次性的无热原，无内毒素试管。 2.血浆：抗凝剂推荐使用EDTA.Na2，标本采集后30分钟内于1000×g离心15分钟，取上清即可 检测。避免使用溶血，高血脂标本。 3.组织匀浆：用预冷的PBS (0.01M, pH=7.4)冲洗组织，以去除残留血液（匀浆中裂解的红细胞 会影响测量结果），称重后将组织剪碎。将剪碎的组织与对应体积的PBS（一般按1:9的重量体积比，比如1g的组织样本对应9mL的PBS，具体体积可根据实验需要适当调整，并做好记录。推荐在PBS中加入蛋白酶抑制剂）加入玻璃匀浆器中，于冰上充分研磨。为了进一步裂解组织细胞，可以对匀浆液进行超声破碎，或反复冻融。最后将匀浆液于5000×g 离心5~10分钟，取上清检测。 4.细胞培养上清：取细胞培养上清于1000×g离心20分钟，除去杂质及细胞碎片。取上清检测。 5.其它生物标本：1000×g离心20分钟，取上清即可检测 （具体处理方法可参考：https://www.360docs.net/doc/ef5612512.html,/news2.asp?tid=477 ） 6.标本应清澈透明，悬浮物应离心去除。 7.标本收集后若不及时检测，请按一次使用量分装，冻存于-20℃/-80℃冰箱内，避免反复冻融， 1-6月内检测,4℃保存的应在1周内进行检测。 8.如果您的样本中检测物浓度高于标准品最高值，请根据实际情况，做适当倍数稀释(建议先做 预实验，以确定稀释倍数)。 试验所需自备物品: 1.酶标仪(450nm波长滤光片) 2.高精度移液器，EP管及一次性吸头：0.5-10μL, 2-20μL, 20-200μL, 200-1000μL 3.37℃恒温箱, 双蒸水或去离子水 4.吸水纸
基英肽(GENEPEPTIDE)研发备忘录、
1991年全球第一个抗肿瘤生物基因药基英肽在美国诞生，美国华盛顿生物第一试验室里，显微镜观察：肿瘤细胞在3小时之内完全萎缩、凋亡。基英肽可以直接切断人体肿瘤细胞DNA链，这一结果轰动了整个世界，做为研发人，威廉·哈里森博士被誉为“GENEPEPTIDE之父”。 美国权威肿瘤专家泰勒·佛兰克教授指出，GENEPEPTIDE(基英肽)之所以效果与众不同是因为：1、直接作用于肿瘤细胞的基因DNA链使其断裂，导致肿瘤细胞迅速凋亡。2、在杀死肿瘤细胞的同时迅速激活吞噬细胞、NK细胞、TB细胞亚群，诱生干扰素和白细胞介素，使机体重新建立起抗肿瘤自愈能力。 抗肿瘤，中国有了自主生物基因药 专家分析：肿瘤的病因是基因突变，患者最需要的是时间，但传统治疗弊端大：手术只能切除可见瘤体；中药只有调理作用，不能直接杀死肿瘤细胞，且见效慢，往往来不及；放化疗副作用大；保健品更无任何治疗作用。早在2000年6月世界卫生组织(WHO)就曾宣布：从DNA入手是治疗肿瘤的关键。 2002年，首例克隆羊“阳阳”、“元元”的诞生地、中国基因研究基地陕西省科学院运用首创的“基因识别技术”，终于研制出了基因抗肿瘤国家级准字号药物基英肽(第三代)，比美国研制的第一代基英肽有效率高13%，比英国、德国研制的第二代基英肽有效率高7%。该药不但可以直接杀死原发病灶及转移病灶的肿瘤细胞，还能准确捕杀血液、淋巴液中游离的肿瘤细胞。基英肽的药盒及说明书上明确标注“药理作用”为：“可切断肿瘤细胞DNA链，使之凋亡”，是国内唯一一个可代替手术、放化疗的基因抗肿瘤药。该药只切断肿瘤细胞DNA 链，不杀伤正常细胞，因而无不良反应。因基英肽能直接杀死肿瘤细胞，所以适用于各个时期及各类肿瘤(肺、肝、胃、食道、肠、胰腺、肾、骨、脑瘤、膀胱、乳腺、子宫、卵巢、鼻咽、前列腺、淋巴瘤、白血病等)。 目前很多药品均宣称能杀死肿瘤细胞，但只有基英肽是国内唯一经国家严格审批被批准在药盒及说明书上明确标注药理作用为：“可切断肿瘤细胞DNA链，使之凋亡”的药物。该药为超浓缩液体剂型，5分钟内药物有效成分就可到达全身血液、淋巴系统及发病组织器官。经国内31家三甲医院临床验证：基英肽对肿瘤患者的疼痛、食欲差、发热、咳嗽、胸闷憋气等用药3-7天就能改善；10天左右放化疗所带来的脱发、恶心呕吐即可减轻，白细胞、血小板数量可逐步升高；用药2周左右，疼痛、黄疸能大幅减轻，积液和腹水大幅减少甚至消失；用药1-2个疗程后肿瘤标志物下降，肿块开始缩小。 老父自寻药助儿战肿瘤 幸福家庭突遭噩耗 2006年3月28日，家住青岛市市北区敦化路的王伟峰，因吞咽困难、大便颜色发黑经山大医院检查被确诊为粘液性胃贲门肿瘤，晚期，肿瘤已转移至胰腺及腹膜后淋巴结，伴随贫血……已经无法手术。晴天霹雳般的噩耗降临在这个幸福的家庭，让王伟峰走向了崩溃的边缘，而此时，他年仅36岁，有自己的爱人，
C肽(C—Peptide)测定试剂盒(化学发光法) 产品技术要求广州科方生物
C肽（C-Peptide）测定试剂盒 （化学发光法） 2.性能指标 2.1试剂盒性能指标 2.1.1外观 试剂盒包装应完整，各组分应齐全，品名、批号和有效期应清晰。各瓶试剂外观应完整，标签应清晰，无破损，无渗漏。M 试剂为黄褐色磁微球悬浮液，沉淀属于正常现象； R 试剂、R2 试剂为澄清透亮液体，没有沉淀和悬浮物。 2.1.2净含量 试剂盒各规格净含量应符合表1的要求。 表1 净含量要求 2.1.3空白限 空白限应不高于 0.03ng/mL。 2.1.4线性 线性范围 0.2ng/mL～30ng/mL，相关系数 r 应不低于 0.9900。 2.1.5准确度
用国家标准品（150553）作为样本进行检测，国家标准品测定结果的相对偏差应不高于 15%。 2.1.6精密度 2.1.6.1批内精密度：变异系数（CV）应≤8%。 2.1.6.2批间精密度：变异系数（CV）应≤15%。 2.1.7特异性 测定浓度为10ng/mL的人胰岛素原，其测定结果应不高于0.25ng/mL；测定浓度为500μIU/mL的人胰岛素，其测定结果应不高于0.25ng/mL。
2.2校准品性能指标 2.2.1外观 校准品外包装应完整，标签标示应清晰。产品为块状或疏松状干粉，溶解后为轻微浑浊液体。 2.2.2水分含量 校准品含水量：≤10% 2.2.3校准品赋值准确性 用经校准品校准的化学发光免疫分析仪检测国家标准品（150553），结果的偏倚在±10%内。 2.2.4均匀性 a）瓶内均匀性：CV 值≤10%； b）瓶间均匀性：CV值≤15%。 2.3质控品性能指标 2.3.1外观 质控品外包装应完整，标签标示应清晰。产品为块状或疏松状干粉，溶解后为轻微浑浊液体。 2.3.2水分含量 质控品含水量：≤10%。 2.3.3预期结果 用经校准品校准的化学发光免疫分析仪检测质控物，结果应在靶值范围内。 2.3.4均匀性 a）瓶内均匀性：CV 值≤10%； b）瓶间均匀性：CV值≤15%。
Peptide Coupling Reagents
Technical Reports Volume 4, Number 1 Peptide Coupling Reagents: Names, Acronyms and References Larry Yet, Ph.D. Medicinal Chemistry Department Albany Molecular Research, Inc. 21 Corporate Circle Albany, NY 12203 ′ Abstract.The following are the names, acronyms and references of commonly used peptide coupling reagents.
The most commonly used reagent in peptide synthesis is 1,3-dicyclohexylcarbodiimide (DCC, see Table 1). Typically, DCC is added to a concentrated solution of carboxylic acid (1 eq), amine (1 eq), and catalyst (when used) in methylene chloride or acetonitrile. The hydrated DCC adduct, dicyclohexylurea (DCU) quickly precipitates from the solution; however, usually DCU remains in solution with the product which makes purification more difficult. Water-soluble derivatives such as 1-ethyl-3-(3’-dimethylaminopropyl)carbodiimide hydrochloride, (EDCI) have been developed to obviate this problem. The urea produced is water-soluble and easily removed by extraction. Problems associated with carbodiimide couplings include unwanted side reactions such as N-acylurea formation and racemization via formation of an oxazalone intermediate. These problems are alleviated by addition of coupling additives, which are also useful for the coupling of sterically hindered components or when the amine is weakly nucleophilic. The most common peptide coupling additive is 1-hydroxybenzotriazole (HOBt), used either in combination with a carbodiimide or another coupling reagent. The additives served to inhibit side reactions and reduce racemization. More recently, 1-hydroxy-7-azabenzotriazole (HOAt) has been described to be a more efficient additive which speeds up coupling processes, reduces the loss of chiral integrity, and provides a visual indication (yellow to colorless) of the reaction endpoint. 3-Hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine (H ODhbt), carbonyldiimidazole (CDI), N-ethyl-5-phenylisoxazolium-3’-sulfonate (NEPIS, Woodward’s Reagent), and hydroxysuccinimide (HOSu) are used less frequently as additives in peptide couplings. Table 1. Commonly Used Peptide Coupling Reagents and Activating Additives N N N OH N N N N HOBt K?nig 1970 N N Me N Me C N ·HCl EDCI Sheehan 1961 HOAt Carpino 1993a HODhbt K?nig 1970 N C N HOSu Wünsch 1966 N O OH DCC Sheehan 1955 Et N N N N CDI Staab 1957 O N Et SO3 NEPIS Woodward 1961
人C肽(C-Peptide)ELISA试剂盒说明书
人C肽（C-Peptide）酶联免疫分析 试剂盒使用说明书 厦门慧嘉生物科技有限公司 本试剂盒仅供研究使用 预期应用 ELISA法定量测定人血清、血浆、细胞培养物上清或其它相关液体中C-Peptide含量。 实验原理 本试剂盒应用双抗体夹心酶标免疫分析法测定标本中C-Peptide水平。用纯化的抗体包被微孔板，制成固相抗体，往包被单抗的微孔中依次加入C-Peptide抗原、生物素化的抗人C-Peptide 抗体、HRP标记的亲和素，经过彻底洗涤后用底物TMB显色。TMB在过氧化物酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的C-Peptide呈正相关。用酶标仪在450nm波长下测定吸光度（OD值），计算样品浓度。 试剂盒组成及试剂配制 1.酶联板：一块（96孔） 2.标准品（冻干品）：2瓶，每瓶临用前以样品稀释液稀释至1ml，盖好后静置10分钟以上， 然后反复颠倒/搓动以助溶解，其浓度为20,000 pg/mL，做系列倍比稀释后，分别稀释成20,000 pg/mL, 10,000 pg/mL，5,000 pg/mL ，2,500 pg/mL，1,250 pg/mL，625 pg/mL，312 pg/mL，其原液直接作为最高标准浓度，样品稀释液直接作为标准浓度0 pg/mL，临用前15分钟内配制。 如配制10,000 pg/mL标准品：取0.5ml 20,000 pg/mL的上述标准品加入含有0.5ml样品稀释液的Eppendorf管中，混匀即可，其余浓度以此类推。 3.样品稀释液：1×20ml/瓶。 4.检测稀释液A：1×10ml/瓶。 5.检测稀释液B：1×10ml/瓶。 6.检测溶液A：1×120ul/瓶（1：100）临用前以检测稀释液A 1：100稀释，稀释前根据预先 计算好的每次实验所需的总量配制（每孔100ul），实际配制时应多配制0.1-0.2ml。如1ul 检测溶液A加99ul检测稀释液A的比例配制，轻轻混匀，在使用前一小时内配制。 7.检测溶液B：1×120ul/瓶（1：100）临用前以检测稀释液B1：100稀释。稀释方法同检测 溶液A。 8.底物溶液：1×10ml/瓶。 9.浓洗涤液：1×30ml/瓶，使用时每瓶用蒸馏水稀释25倍。 10.终止液：1×10ml/瓶（2N H2SO4）。 标本的采集及保存 1．细胞培养物上清：请离心后收集上清，并将标本保存于-20℃，且应避免反复冻融。 2．血清：标本请于室温放置2小时或4℃过夜后于1000 x g离心20分钟，取上清即可检测，或将标本放于-20℃保存，但应避免反复冻融。 3．血浆：可用EDTA或肝素作为抗凝剂，标本采集后30分钟内于2 - 8° C 1000 x g离心15分钟，或将标本放于-20℃保存，但应避免反复冻融。 注：标本溶血会影响最后检测结果，因此溶血标本不宜进行此项检测。
Peptide Cleavage_protocols
TECHNICAL BULLETIN Cleavage, Deprotection, and Isolation of Peptides after Fmoc Synthesis Potential Problems Cleavage and deprotection is one of the most crucial steps in peptide synthesis. The treatment of a peptidyl-resin with a cleavage cocktail is not one simple reaction, but a series of competing reactions. Unless suitable reagents and reaction conditions are selected, the peptide can be irreversibly modified or damaged. Certain amino acids can cause problems during TFA cleavage and deprotection. These fall into three broad categories: 1. Amino acids whose protecting groups are easily removed, but whose deprotected side-chains are especially labile in acid conditions (e.g., Met, Cys, His, Trp ). The goal of cleavage/deprotection is to separate the peptide from the support while removing the protecting groups from the side-chains. This should be done as quickly as possible to minimize the exposure of the peptide to the cleavage reagent. The peptide is then recovered from the reaction mixture and analyzed. This technical bulletin describes procedures for cleavage of peptides from solid supports assembled via Fmoc/t Bu-based strategies.1 2. Amino acids which need more than the normal two hours for complete removal of the side-chain protecting groups (e.g., Arg(Pmc/Mtr), Asn/Gln(Mbh)). 3. Amino acids whose side-chain protecting groups, once removed from the side-chain, are extremely reactive and must be scavenged to prevent reattachment or modification of the deprotected side-chains (e.g., Arg(Pmc/Mtr), Asn/Gln(Tmob)). There are numerous procedures in the literature which describe a variety of cleavage and deprotection methods for peptides synthesized with an Fmoc/t Bu strategy.2-4 . Most of these techniques are TFA-based, and they differ primarily in the final concentration of TFA, types of scavengers used, and reaction times. Some of the variablity in methods reflects the preferences of individual labs, but it is mainly dictated by the amino acid composition of the peptide. Table 1: Side-chain Protecting Groups for Fmoc Amino Acids Amino acid Protecting Group (bold is recommended) Functionality Protected Ala (A) none Arg (R) Pbf , Mtr, Pmc guanidino N Asn (N) Trt , Mbh, Tmob Amide Asp (D) O t Bu , OAl °, Carboxyl Cys (C) Trt, Acm °, t Bu °, St Bu Sulfhydryl Gln (Q) Trt , Mbh, Tmob, Amide Glu (E) O t Bu, OAl ° Carboxyl Gly (G) none His (H) Trt , Boc Imidazole Ile (I) none Leu (L) none Lys (K) Boc , Aloc °, Fmoc ° Amino Met (M) none Orn (O) Boc Amino Phe (F) none Pro (P) none Ser (S) t Bu Hydroxyl Thr (T) tBu Hydroxyl Trp (W) Boc Indole Tyr (Y) t Bu Phenol Val (V) none Some amino acids have potentially reactive side-chains which generate carbonium ions and other reactive species during TFA cleavage of the peptide from the support. Therefore, the appropriate scavengers and reaction conditions must be chosen to minimize modification or destruction of the sensitive amino acids. Since prolonged treatment with the cleavage acid is needed to remove some protecting groups, scavengers must be used to protect the reactive sites of the peptide during extended reaction times. The 21 naturally-occurring Fmoc amino acids and their side-chain protecting groups are listed in Table 1. -------------------------------------------------------------------------- Abbreviations: Acm: acetamidomethyl, ACN: acetonitrile, Al: allyl, Ala: alanine, Aloc: allyloxycarbonyl , Arg: arginine, Asn : asparagine, Asp : aspartic acid, Boc: t -butyloxycarbonyl, Cys : cysteine, DCM: dichloromethane, DMF: N,N -dimethylformamide, DTT: dithiothreitol, EDT : 1,2-ethanedithiol, Fmoc: 9-fluorenylmethoxycarbonyl, Gln : glutamine, Glu: glutamic acid, Gly : glycine, His : histidine, HPLC: high performance liquid chromatography, Ile : isoleucine, Leu: leucine, Lys : lysine, Mbh : 4,4-dimethyloxybenzhydryl, MeOH: methanol, Met: methionine, Mtr: methoxytrimethylbenzene sulfonyl, OAl : allyl ester, Orn: ornithine, O t Bu: t -butyl ester, Pbf: 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl, pGlu: pyroglutamic acid or pyrrolidone glutamic acid, Phe: phenylalanine, Pmc : 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl chloride, Pro : proline, SDS: sodium dodecyl sulfate, Ser : serine, t Bu : t -butyl ether, TES: triethylsilane, TFA: trifluoroacetic acid, Thr : threonine, TIPS : triisopropylsilane, Tmob : 2,4,6-trimethoxybenzyl, Trp: tryptophan, Trt : trityl or triphenylmethyl, Tyr: tyrosine, Val : valine ° Indicates protecting groups not removed by TFA Methionine Peptides containing methionine are easily oxidized to methionine sulfoxide, which can be reduced back to methionine by treatment with dithiothreitol (DTT) or N -mercaptoacetamide 2,3 . The conversion of methionine sulfoxide back to methionine can be monitored by reverse-phase HPLC, since the sulfoxide is more polar, eluting slightly earlier. Short deprotection times will greatly reduce the amount of oxidation that occurs.